Get the Stockscreener App
3.25
0.61%
-0.02
Pre-market:
3.12
-0.13
-4.00%
Atea Pharmaceuticals Inc stock is traded at $3.25, with a volume of 660.48K.
It is down -0.61% in the last 24 hours and up +12.07% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$3.27
Open:
$3.27
24h Volume:
660.48K
Relative Volume:
1.89
Market Cap:
$257.91M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.57
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
+1.25%
1M Performance:
+12.07%
6M Performance:
+10.17%
1Y Performance:
+0.31%
1-Day Range:
$3.20
$3.275
1-Week Range:
$3.15
$3.335
52-Week Range:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.25 | 259.50M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Is a relief rally coming for Atea Pharmaceuticals Inc. holdersJuly 2025 Big Picture & Free Long-Term Investment Growth Plans - newser.com
Is Atea Pharmaceuticals Inc. still worth holding after the dipBuy Signal & Consistent Return Investment Signals - newser.com
Atea Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Update & Verified Momentum Watchlists - newser.com
Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataJuly 2025 Big Picture & Free Long-Term Investment Growth Plans - newser.com
Is Atea Pharmaceuticals Inc. stock cheap at current valuation2025 Market Overview & High Accuracy Swing Entry Alerts - newser.com
Backtesting results for Atea Pharmaceuticals Inc. trading strategiesJuly 2025 Intraday Action & Short-Term Trading Alerts - newser.com
Atea Pharmaceuticals, Inc. (AVIR) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Atea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/Ruzasvir - MSN
Live market analysis of Atea Pharmaceuticals Inc.2025 Momentum Check & Daily Stock Momentum Reports - newser.com
Atea Pharmaceuticals Inc Stock Analysis and ForecastFlag and Pennant Patterns & Outstanding Portfolio Growth - earlytimes.in
Atea Pharmaceuticals, Inc. (AVIR) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Applying sector rotation models to Atea Pharmaceuticals Inc.Weekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Using economic indicators to assess Atea Pharmaceuticals Inc. potentialMarket Growth Review & Free Fast Gain Swing Trade Alerts - newser.com
What drives Atea Pharmaceuticals Inc stock priceDividend Reinvestment Plans & Free Fastest Return On Investment - earlytimes.in
Will Atea Pharmaceuticals Inc. stock split attract more investorsIPO Watch & Daily Profit Maximizing Trade Tips - fcp.pa.gov.br
Will Atea Pharmaceuticals Inc. stock continue dividend increasesWeekly Trading Summary & Reliable Entry Point Alerts - fcp.pa.gov.br
Atea Pharmaceuticals’ New HCV Study: Potential Game-Changer? - TipRanks
Atea Pharmaceuticals’ Promising HCV Treatment Study: Key Insights for Investors - TipRanks
Custom strategy builders for tracking Atea Pharmaceuticals Inc.Dollar Strength & Capital Efficiency Focused Ideas - newser.com
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):